US equities
|
SPCX
$171.09
▲+0.00%
NVDA
$238.90
▲+0.00%
MU
$1,063.96
▲+0.00%
AMZN
$251.40
▲+0.00%
META
$741.90
▲+0.00%
AMD
$631.75
▲+0.00%
SNDK
$1,704.16
▲+0.00%
TSLA
$378.73
▲+0.00%
SPCX
$171.09
▲+0.00%
NVDA
$238.90
▲+0.00%
MU
$1,063.96
▲+0.00%
AMZN
$251.40
▲+0.00%
META
$741.90
▲+0.00%
AMD
$631.75
▲+0.00%
SNDK
$1,704.16
▲+0.00%
TSLA
$378.73
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Fulcrum Therapeutics, Inc. - Common Stock
(NQ:
FULC
)
3.710
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Fulcrum Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Tuesday's session: gap up and gap down stocks
↗
June 02, 2026
Via
Chartmill
Stay updated with the stocks that are on the move in today's pre-market session.
↗
June 02, 2026
Via
Chartmill
Which stocks are moving after the closing bell on Monday?
↗
June 01, 2026
Via
Chartmill
Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review
June 01, 2026
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics (NASDAQ:FULC) Beats Q1 Estimates as Pociredir Data Fuels Optimism
↗
April 27, 2026
Via
Chartmill
Fulcrum Therapeutics (NASDAQ:FULC) Q4 2025 Earnings: Pociredir Data Steals Spotlight Amid In-Line Financials
↗
February 24, 2026
Via
Chartmill
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 08, 2026
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum (FULC) Q1 2026 Earnings Transcript
↗
April 27, 2026
Fulcrum (FULC) Q1 2026 Earnings Transcript
Via
The Motley Fool
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
April 27, 2026
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors
April 27, 2026
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET
April 20, 2026
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Sarepta's RNA Renaissance: 35% Surge as siRNA Breakthrough Silences Skeptics
March 26, 2026
CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ: SRPT) skyrocketed 35% in early trading today, reaching levels not seen since the company’s early days in Duchenne Muscular...
Via
MarketMinute
Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data
March 26, 2026
CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ:SRPT) skyrocketed 34.98% in heavy trading today, marking the biotech giant's most explosive single-day gain in over two years....
Via
MarketMinute
MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease
March 19, 2026
Three-year collaboration is aimed at enhancing a key aspect of sickle cell management: expediting care during a pain crisis
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2026
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
March 03, 2026
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
February 24, 2026
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
February 24, 2026
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
February 17, 2026
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2026
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 09, 2026
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 07, 2026
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
December 10, 2025
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
ENDRA Life Sciences (NASDAQ: NDRA) Advances TAEUS® Liver Imaging, Strengthens Capital Efficiency; WVE, TWG, BDRX, FULC Also Active
December 09, 2025
Via
AB Newswire
Let's take a look at the stocks that are in motion in today's session.
↗
December 08, 2025
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.
Via
Chartmill
What's going on in today's session
↗
December 08, 2025
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via
Chartmill
There are notable gap-ups and gap-downs in today's session.
↗
December 08, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.
Via
Chartmill
Wondering what's happening in today's pre-market session?
↗
December 08, 2025
Wondering what's happening in Monday's pre-market session? Find an overview in this article.
Via
Chartmill
Fulcrum Stock Nears March 2024 Highs: Early Stage Sickle-Cell Data Sparks Target Price Hikes
↗
December 08, 2025
On Saturday, the company reported promising early outcomes from its Phase 1b PIONEER trial for sickle cell disease (SCD).
Via
Stocktwits
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
December 06, 2025
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
